OSR:HAMOSRAM Licht AG Analysis

OSR Health trades at $0.4672, which sits modestly above its DCF‑derived fair value of $0.4167, suggesting a slight premium despite a strikingly low price‑to‑book multiple of 0.15 versus a book value of $3.12 per share. Technical indicators are mixed: the 20‑day SMA (0.354) and 50‑day SMA (0.431) are both below the current price, while the 200‑day SMA (0.543) remains well above, confirming a bearish long‑term trend; however, the MACD histogram is positive (0.023) and the MACD signal is bullish, and RSI sits at 64.9, hinting at short‑term momentum. Volume is increasing, but the market cap is only $16.4 M, indicating limited liquidity. Fundamentally, the company reports a negative operating margin of –7.6 % and a gross margin of just 20.9 %, with operating cash flow deeply negative at –$5.27 M, while debt‑to‑equity is high at 3.89, reflecting financial strain. The PE ratio of 15.6 is well below the biotechnology industry average of 28.99, pointing to relative undervaluation on a earnings basis, yet the max drawdown of 71 % and 30‑day volatility of ~90 % underscore extreme price swings. No dividend is paid, eliminating income‑generation considerations.